You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
4 June 2024
Spexis launches appeal against SIX Exchange Regulation decision to suspend trading of its shares.
31 May 2024
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
30 April 2024
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
17 April 2024
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
8 February 2024
Spexis announces closing of sale of preclinical antibiotics program to Basilea
15 January 2024
Spexis announces sale of preclinical antibiotics program to Basilea
18 July 2023
Original-Research: Spexis AG (von First Berlin Equity Research GmbH): Buy
25 January 2023